<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:department>Biological Sciences</gtr:department><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/41E2AFEC-6993-4412-8CD9-D75C7BC9E223"><gtr:id>41E2AFEC-6993-4412-8CD9-D75C7BC9E223</gtr:id><gtr:firstName>Emma</gtr:firstName><gtr:otherNames>Clare</gtr:otherNames><gtr:surname>Anderson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701220"><gtr:id>BF70D065-9CA9-412D-BE41-9EF928CC118B</gtr:id><gtr:title>Regulation of translation of human immunodeficiency virus type-1 RNA by the viral Gag protein</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701220</gtr:grantReference><gtr:abstractText>We are studying part of the life cycle of human immunodeficiency virus (HIV) to understand how the virus makes the proteins for new infectious particles. This is important as it may help to uncover new targets for anti-HIV therapy.
More than forty million people worldwide are infected with HIV, and 3 million people die of AIDS-related illnesses every year. Despite the development of drugs which can delay the onset of AIDS, resistance to the current drugs is common, and there is no cure. New therapies are needed, requiring more knowledge about the HIV life cycle.
One area of the life cycle that we are interested in is how the virus makes its proteins. HIV uses the cell?s machinery to do this, but it is not known how the virus is able to compete with normal cell protein production. The purpose of this research project is to investigate how HIV interacts with the cell?s machinery to promote viral protein production, and to see what happens to the virus when we disrupt this interaction. We hope that the results of this research may suggest a new area of the HIV life cycle to target with drug therapy.</gtr:abstractText><gtr:technicalSummary>40 million people around the world are infected with human immunodeficiency virus type-1 (HIV-1), the aetiological agent of AIDS. Despite much research on the virus, and the development of highly active antiretroviral therapy, drug-resistant strains of HIV-1 are emerging. Alternative therapeutic targets are needed, necessitating the investigation of under-explored steps in HIV replication. One such area is that of translation of the viral RNA. The study of translation in other viruses has resulted in huge leaps forward in the understanding and treatment of human disease, but little is known about how HIV translation is regulated. 

Translation of the full-length HIV-1 RNA is especially complex. This RNA encodes the viral structural protein Gag, and is also the genomic RNA that is packaged into new viral particles by Gag. There must therefore be an equilibrium between translation and packaging of the full-length HIV-1 RNA to enable sufficient Gag production before a switch to particle production. The viral Gag protein plays a crucial role in controlling the translation of the HIV-1 RNA ? at low concentrations, it stimulates translation to make more Gag protein. As the concentration of Gag increases, it binds to the HIV-1 RNA, inhibits translation and initiates encapsidation.

Gag has been shown to bind to the eukaryotic translation initiation factor 5B (eIF5B), and preliminary results suggest that this interaction is required for Gag to stimulate translation of HIV-1 RNA. The first aim of this proposal is to characterise the interaction between Gag and eIF5B by developing recombinant viruses that are unable to bind eIF5B, and determining the importance of this interaction for HIV-1 replication. The second aim of the proposal is to investigate the mechanism by which the Gag-eIF5B complex stimulates translation in biochemical assays.

Knowledge of the fundamental process of translation in HIV-1 should lead to new potential drug targets and subsequently new therapies, such as small molecule inhibitors of Gag-eIF5B complex formation.</gtr:technicalSummary><gtr:fund><gtr:end>2012-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>345810</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pathology</gtr:department><gtr:description>PD</gtr:description><gtr:id>EC797633-5639-4F62-B712-D6A14CA4D970</gtr:id><gtr:impact>PMID 19494001</gtr:impact><gtr:outcomeId>nyjrpJUXW5x-1</gtr:outcomeId><gtr:partnerContribution>Intellectual and experimental contribution</gtr:partnerContribution><gtr:piContribution>Intellectual input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>AML</gtr:description><gtr:id>D112F645-8430-4DF6-89B8-9353EAA13995</gtr:id><gtr:impact>PMID 19264599 and 19321757</gtr:impact><gtr:outcomeId>5AA5EA95740-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input</gtr:partnerContribution><gtr:piContribution>Intellectual input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>A level Biology Conference (London)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2F88ACA8-A5A1-4932-81BA-832EA3364147</gtr:id><gtr:impact>100 A level biology students and their teachers attended talks on important topics in biology, including my talk on HIV, which sparked discussion and questions afterwards. The aim was to inspire more students, particularly from underprivileged areas, to apply to University to study biology.

Schools have shown increased interest in the talks, and the conference organisers have made podcasts of our talks for schools who were unable to attend the conference.</gtr:impact><gtr:outcomeId>544795ba1db679.14430226</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UNICEF World AIDS Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3615FDC2-C3FC-455C-AB74-A6FFF5911845</gtr:id><gtr:impact>Around 50 people attended UNICEF World AIDS Day Summit for talks and discussion.

Public more aware of research done on HIV to combat AIDS.</gtr:impact><gtr:outcomeId>AK8WcfLeZ8a</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open Days</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DC052F04-B28C-4469-8F89-782A28647FB5</gtr:id><gtr:impact>600-800 school children and parents attended Open Day, which I partly organised.

Increased number of applicants to study life science courses.</gtr:impact><gtr:outcomeId>5447985d5e1103.81123482</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013,2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Biology Headstart Course</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>42226F0F-D11B-40A8-BA4A-10252F34E63E</gtr:id><gtr:impact>Sixth form biology students from a diverse range of backgrounds, selected for Biology Headstart Course, attended Warwick University for week-long course to introduce them to Higher Education. Gave a talk on admissions, teaching and research, which sparked questions and discussion afterwards. The University saw increased applications for biology courses from widening participation students.</gtr:impact><gtr:outcomeId>56d99181eadea7.06597753</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Warwick Impact Fund</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>University of Warwick</gtr:fundingOrg><gtr:id>F2FEE2CE-9BB3-4F54-8CB6-F281866166ED</gtr:id><gtr:outcomeId>544793e77b2d74.51100977</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Chimeric viruses.</gtr:description><gtr:id>99523D5D-F449-4FB5-A7EF-9C4E64E44C62</gtr:id><gtr:impact>Development of new area of research</gtr:impact><gtr:outcomeId>CToha3VTP8r</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>MA2 and MA1</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7B5A5CDE-A8C1-40DC-86C1-B2384C93D95C</gtr:id><gtr:title>Rev: beyond nuclear export.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1967f1ef6807f4bedadc0b6799a69e9a"><gtr:id>1967f1ef6807f4bedadc0b6799a69e9a</gtr:id><gtr:otherNames>Groom HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>E264AACCB49</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3219DB91-CB41-4AFD-B243-95F544475ED4</gtr:id><gtr:title>A complicated message: Identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16a3e92067207f4070e69b1efa752940"><gtr:id>16a3e92067207f4070e69b1efa752940</gtr:id><gtr:otherNames>Wise HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>PwgE4VCJsEc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C3943C7-63B8-4E2C-98DA-F59FD92D1C2C</gtr:id><gtr:title>A new role for clathrin adaptor proteins 1 and 3 in lipoplex trafficking.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7252c2fd6a064cdaa28a91f4894c732f"><gtr:id>7252c2fd6a064cdaa28a91f4894c732f</gtr:id><gtr:otherNames>Alford JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544790fab85688.08119685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>473EE075-1299-49C3-9B8B-0F9D853FDF2E</gtr:id><gtr:title>Overlapping signals for translational regulation and packaging of influenza A virus segment 2.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16a3e92067207f4070e69b1efa752940"><gtr:id>16a3e92067207f4070e69b1efa752940</gtr:id><gtr:otherNames>Wise HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>rtBfVP1pYr5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D30D3B5-2280-434A-AA76-393FB7FAF306</gtr:id><gtr:title>Rev regulates translation of human immunodeficiency virus type 1 RNAs.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1967f1ef6807f4bedadc0b6799a69e9a"><gtr:id>1967f1ef6807f4bedadc0b6799a69e9a</gtr:id><gtr:otherNames>Groom HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>366C8F3D5CE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2671E7EB-09E2-4108-A8CA-EF703A244D37</gtr:id><gtr:title>Human Immunodeficiency Virus Type 2 (HIV-2) Gag Is Trafficked in an AP-3 and AP-5 Dependent Manner.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7252c2fd6a064cdaa28a91f4894c732f"><gtr:id>7252c2fd6a064cdaa28a91f4894c732f</gtr:id><gtr:otherNames>Alford JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a9fe63b706361.59260688</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701220</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>